AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.

AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...

Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...

US drugmaker AbbVie is to acquire Nimble Therapeutics, a USA-based Roche spinout developing oral peptide treatments in the ...

Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions ...

Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...